C-type Lectin Receptors for Tumor Eradication: Future Directions

Ingeborg Streng-Ouwehand, Wendy W J Unger, Yvette Van Kooyk

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Dendritic cells are key regulators in directing immune responses and therefore are under extensive research for the induction of anti-tumor responses. DCs express a large array of receptors by which they scan their surroundings for recognition and uptake of pathogens. One of the receptor-families is the C-type lectins (CLR), which bind carbohydrate structures and internalize antigens upon recognition. Intracellular routing of antigen through CLR enhances loading and presentation of antigen through MHC class I and II, inducing antigen-specific CD4+ and CD8+ T-cell proliferation and skewing T-helper cells. These characteristics make CLRs very interesting targets for DC-based immunotherapy. Profound research has been done on targeting specific tumor antigens to CLR using either antibodies or the natural ligands such as glycan structures. In this review we will focus on the current data showing the potency of CLR-targeting and discuss improvements that can be achieved to enhance anti-tumor activity in the near future.

Original languageEnglish
Pages (from-to)3169-88
Number of pages20
JournalCancers
Volume3
Issue number3
DOIs
Publication statusPublished - 8 Aug 2011

Cite this

Streng-Ouwehand, Ingeborg ; Unger, Wendy W J ; Van Kooyk, Yvette. / C-type Lectin Receptors for Tumor Eradication : Future Directions. In: Cancers. 2011 ; Vol. 3, No. 3. pp. 3169-88.
@article{379e3e3691754e25bb97ad41e9f1fdec,
title = "C-type Lectin Receptors for Tumor Eradication: Future Directions",
abstract = "Dendritic cells are key regulators in directing immune responses and therefore are under extensive research for the induction of anti-tumor responses. DCs express a large array of receptors by which they scan their surroundings for recognition and uptake of pathogens. One of the receptor-families is the C-type lectins (CLR), which bind carbohydrate structures and internalize antigens upon recognition. Intracellular routing of antigen through CLR enhances loading and presentation of antigen through MHC class I and II, inducing antigen-specific CD4+ and CD8+ T-cell proliferation and skewing T-helper cells. These characteristics make CLRs very interesting targets for DC-based immunotherapy. Profound research has been done on targeting specific tumor antigens to CLR using either antibodies or the natural ligands such as glycan structures. In this review we will focus on the current data showing the potency of CLR-targeting and discuss improvements that can be achieved to enhance anti-tumor activity in the near future.",
author = "Ingeborg Streng-Ouwehand and Unger, {Wendy W J} and {Van Kooyk}, Yvette",
year = "2011",
month = "8",
day = "8",
doi = "10.3390/cancers3033169",
language = "English",
volume = "3",
pages = "3169--88",
journal = "Cancers (Basel)",
issn = "2072-6694",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "3",

}

C-type Lectin Receptors for Tumor Eradication : Future Directions. / Streng-Ouwehand, Ingeborg; Unger, Wendy W J; Van Kooyk, Yvette.

In: Cancers, Vol. 3, No. 3, 08.08.2011, p. 3169-88.

Research output: Contribution to journalArticleAcademicpeer-review

TY - JOUR

T1 - C-type Lectin Receptors for Tumor Eradication

T2 - Future Directions

AU - Streng-Ouwehand, Ingeborg

AU - Unger, Wendy W J

AU - Van Kooyk, Yvette

PY - 2011/8/8

Y1 - 2011/8/8

N2 - Dendritic cells are key regulators in directing immune responses and therefore are under extensive research for the induction of anti-tumor responses. DCs express a large array of receptors by which they scan their surroundings for recognition and uptake of pathogens. One of the receptor-families is the C-type lectins (CLR), which bind carbohydrate structures and internalize antigens upon recognition. Intracellular routing of antigen through CLR enhances loading and presentation of antigen through MHC class I and II, inducing antigen-specific CD4+ and CD8+ T-cell proliferation and skewing T-helper cells. These characteristics make CLRs very interesting targets for DC-based immunotherapy. Profound research has been done on targeting specific tumor antigens to CLR using either antibodies or the natural ligands such as glycan structures. In this review we will focus on the current data showing the potency of CLR-targeting and discuss improvements that can be achieved to enhance anti-tumor activity in the near future.

AB - Dendritic cells are key regulators in directing immune responses and therefore are under extensive research for the induction of anti-tumor responses. DCs express a large array of receptors by which they scan their surroundings for recognition and uptake of pathogens. One of the receptor-families is the C-type lectins (CLR), which bind carbohydrate structures and internalize antigens upon recognition. Intracellular routing of antigen through CLR enhances loading and presentation of antigen through MHC class I and II, inducing antigen-specific CD4+ and CD8+ T-cell proliferation and skewing T-helper cells. These characteristics make CLRs very interesting targets for DC-based immunotherapy. Profound research has been done on targeting specific tumor antigens to CLR using either antibodies or the natural ligands such as glycan structures. In this review we will focus on the current data showing the potency of CLR-targeting and discuss improvements that can be achieved to enhance anti-tumor activity in the near future.

U2 - 10.3390/cancers3033169

DO - 10.3390/cancers3033169

M3 - Article

VL - 3

SP - 3169

EP - 3188

JO - Cancers (Basel)

JF - Cancers (Basel)

SN - 2072-6694

IS - 3

ER -